Literature DB >> 25785084

Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.

Yifan Peng1, Zhiwei Zhai2, Zhongmin Li1, Lin Wang1, Jin Gu1.   

Abstract

AIM: To investigate the prognostic value of carcinoembryonic antigen (CEA), CA199, CA724 and CA242 in peripheral blood and local draining venous blood in colon cancer patients after curative resection.
METHODS: 92 colon cancer patients who received curative resection were retrospectively analyzed. The CEA, CA199, CA724 and CA242 were detected in peripheral blood and local draining venous blood.
RESULTS: Metastasis or local recurrence was found in 29 (29/92, 31.5%) patients during follow-up period. 92 patients were divided into two groups: metastasis/local recurrence group (n = 29) and non-metastasis/local recurrence group (n = 63). Peripheral venous CEA, CA199, CA724 and CA242 (p-CEA, p-CA199, p-CA724 and p-CA242) were comparable between two groups (P > 0.05). The median draining venous CEA (d-CEA) in metastases/local recurrence group (23.7 ± 6.9 ng/ml) was significantly higher than that in non-metastases/local recurrence group (18.1 ± 6.3 ng/ml; P < 0.05), but marked differences were not observed in draining venous CA199, CA724 and CA242 (d-CA199, d-CA724 and d-CA242) between two groups (P > 0.05). The optimal cut-off value of d-CEA was 2.76 ng/ml, with the sensitivity and specificity of 90% and 40% in the prediction of metastasis or local recurrence, respectively. d-CEA correlated with tumor differentiation, T stage, TNM stage, metastasis and local recurrence. Subgroup analysis showed that, of 41 patients with stage II colon cancer, the optimal cut-off value of d-CEA was 8.78 ng/mL, and the sensitivity and specificity were 87.5% and 69.7% in the prediction of metastasis or local recurrence, respectively.
CONCLUSION: d-CEA may be a prognostic factor for stage II colon cancer patients.

Entities:  

Keywords:  Colon cancer; carcinoembryonic antigen; prognosis

Year:  2015        PMID: 25785084      PMCID: PMC4358539     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  36 in total

1.  The serum level of carcinoembryonic antigen in drainage venous blood is not a sensitive predictor of metachronous hepatic metastasis for patients with colorectal cancer.

Authors:  Masashi Haraguchi; Fumihiko Fujita; Yasuhiro Torashima; Takamitsu Inokuma; Yoshitsugu Tajima; Takashi Kanematsu
Journal:  Surg Today       Date:  2010-07-30       Impact factor: 2.549

2.  Colorectal cancer patients with high risk of hematogenous metastasis: correlation with CEA levels in peripheral and draining venous blood during the period of operation.

Authors:  Y Tabuchi; H Deguchi; K Imanishi; Y Saitoh
Journal:  J Surg Oncol       Date:  1991-06       Impact factor: 3.454

3.  Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.

Authors:  Richard C Bates; David I Bellovin; Courtney Brown; Elizabeth Maynard; Bingyan Wu; Hisaaki Kawakatsu; Dean Sheppard; Peter Oettgen; Arthur M Mercurio
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Hiroshi Ohtani; Katsunobu Sakurai; Takahiro Toyokawa; Naoshi Kubo; Hiroaki Tanaka; Kazuya Muguruma; Masaichi Ohira; Kosei Hirakawa
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

5.  Tumor markers in staging and prognosis of colorectal carcinoma.

Authors:  M Levy; V Visokai; L Lipska; O Topolcan
Journal:  Neoplasma       Date:  2008       Impact factor: 2.575

6.  Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Correlation with histopathologic variables.

Authors:  Y Tabuchi; H Deguchi; K Imanishi; Y Saitoh
Journal:  Cancer       Date:  1987-04-01       Impact factor: 6.860

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

8.  [Carcinoembryonic antigen (CEA) levels of peripheral and portal blood and tumor histopathology in colorectal cancer].

Authors:  Y Tabuchi; H Deguchi; K Imanishi; Y Saitoh
Journal:  Nihon Geka Gakkai Zasshi       Date:  1986-12

Review 9.  Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.

Authors:  Laurent Poincloux; Xavier Durando; Jean François Seitz; Emilie Thivat; Valérie-Jeanne Bardou; Marie-Hélène Giovannini; Danièle Parriaux; Nicolas Barriere; Marc Giovannini; Jean-Robert Delpero; Geneviève Monges
Journal:  Surg Oncol       Date:  2008-11-21       Impact factor: 3.279

10.  Carcinoembryonic antigen level of draining venous blood as a predictor of recurrence in colorectal cancer patient.

Authors:  Soo Young Lee; Kyung Sun Min; Jung Kee Chung; In Mok Jung; Young Joon Ahn; Ki-Tae Hwang; Hye Seong Ahn; Seung Chul Heo
Journal:  J Korean Surg Soc       Date:  2011-11-25
View more
  7 in total

1.  Can factors that influence nodal dissemination in patients with colorectal cancer be identified? Own experience.

Authors:  Konrad P Zaręba; Justyna Zińczuk; Tomasz Dawidziuk; Mariusz Rosołowski; Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz; Bogusław Kędra
Journal:  Prz Gastroenterol       Date:  2020-09-19

2.  Prothrombin time (PT) and CEA as prognostic predictive biomarkers for postoperative recurrence after curative resection in patients with stage I-III colorectal cancer: a retrospective cohort study.

Authors:  Lulu Ma; Wenya Li; Ningquan Liu; Zhijie Ding; Jianchun Cai; Yiyao Zhang
Journal:  Updates Surg       Date:  2022-03-24

3.  The prognostic value of preoperative serum CA724 for CEA-normal colorectal cancer patients.

Authors:  Jiaan Kuang; Yizhen Gong; Hailun Xie; Ling Yan; Shizhen Huang; Feng Gao; Shuangyi Tang; Jialiang Gan
Journal:  PeerJ       Date:  2020-04-14       Impact factor: 2.984

4.  Predictive Values of the Selected Inflammatory Indexes in Colon Cancer.

Authors:  Li Huang; Zuojian Hu; Ruixian Luo; Hailan Li; Ziji Yang; Xue Qin; Zhuning Mo
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

5.  Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer.

Authors:  HanZheng Zhao; Xingyu Chen; WenHui Zhang; Die Cheng; Yanjie Lu; Cheng Wang; JunHu Li; LiuPing You; JiaYong Yu; WenLong Guo; YuHong Li; YueNan Huang
Journal:  Front Surg       Date:  2022-08-12

6.  Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy.

Authors:  Feng Zhu; Jing Ma; Dongdong Ru; Ningning Wu; Yunhua Zhang; Huiyuan Li; Xiaoli Liu; Jianfeng Li; Huiling Zhang; Yue Xu; Jiangman Zhao; Hui Tang; Yusheng Wang; Weihua Fu
Journal:  J Oncol       Date:  2021-05-26       Impact factor: 4.375

7.  Prognosis prediction model based on competing endogenous RNAs for recurrence of colon adenocarcinoma.

Authors:  Li Peng Jin; Tao Liu; Fan Qi Meng; Jian Dong Tai
Journal:  BMC Cancer       Date:  2020-10-07       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.